SCHEMBL18922746

SCHEMBL18922746

CCOc1cccc2c1CCO2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.50
HTR2A P28223 4/20 0.50
HTR2B P41595 3/20 0.50
MTNR1B P49286 4/20 0.48
MTNR1A P48039 4/20 0.48
EED O75530 1/20 0.39
SUZ12 Q15022 1/20 0.39
EZH2 Q15910 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
PABPC1 P11940 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CYP2A6 P11509 1/20 0.37
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9456629 0.81 MTNR1A (0.44) HTR2CHTR2AHTR2BMTNR1BMTNR1A
SCHEMBL360947 0.80 MTNR1B (0.50) HTR2CHTR2AHTR2BMTNR1BMTNR1A
SCHEMBL6310248 0.78 ALDH1A1 (0.51) HTR2CHTR2AHTR2BMTNR1BMTNR1A
SCHEMBL6310241 0.78 ALDH1A1 (0.51) HTR2CHTR2AHTR2BMTNR1BMTNR1A
SCHEMBL20978627 0.77 MTNR1A (0.60) MTNR1BMTNR1AALDH1A1NPSR1TSHR
SCHEMBL8405200 0.77 MTNR1B (0.52) MTNR1BMTNR1AALDH1A1MAPTKDM4E
SCHEMBL27937262 0.76 MTNR1A (0.56) MTNR1BMTNR1A
SCHEMBL16659181 0.76 MTNR1B (0.42) HTR2CHTR2AHTR2BMTNR1BMTNR1A
SCHEMBL14405818 0.74 MTNR1B (0.50) MTNR1BMTNR1AEEDSUZ12EZH2
SCHEMBL13818785 0.72 EED (0.44) HTR2CHTR2AHTR2BMTNR1BMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11147813-B2 Modulators of KV3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2021-10-19 US disclosed
US-9669030-B2 Hydantoin derivatives as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2017-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11147813-B2 Modulators of KV3 channels to treat pain KCNN3, KCNA3, KCND3 HTR2C 919/4885HTR2A 1395/4885HTR2B 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.